ライフサイエンスコーパス: neonatal mortality

1 available or feasible in countries with high neonatal mortality.

2 ion of maternal cancer during pregnancy with neonatal mortality.

3 ca achieved marked reductions in under-5 and neonatal mortality.

4 or child mortality than for neonatal or post-neonatal mortality.

5 but fatal outcomes, including stillbirth and neonatal mortality.

6 which this community intervention may affect neonatal mortality.

7 ause significant morbidity and even fetal or neonatal mortality.

8 ), birth injury, low Apgar score (</=8), and neonatal mortality.

9 , and PGF2alpha, resulting in PTB and marked neonatal mortality.

10 The primary outcome was all-cause neonatal mortality.

11 wed a reduction of 8% (95% CI -12 to 25%) in neonatal mortality.

12 itated by ASHAs on birth outcomes, including neonatal mortality.

13 re cannot be expected to reduce maternal and neonatal mortality.

14 resulted in very low levels of maternal and neonatal mortality.

15 but less progress has been made in reducing neonatal mortality.

16 (VD) that was associated with an increase in neonatal mortality.

17 association of facility quality of care with neonatal mortality.

18 ceramide (alpha-GalCer) induced late PTB and neonatal mortality.

19 mary outcome was fresh stillbirth and 28-day neonatal mortality.

20 affected by vesicular disease and increased neonatal mortality.

21 weight loss before pregnancy reduced risk of neonatal mortality.

22 ermine factors associated with postoperative neonatal mortality.

23 ctive hospital-based interventions to reduce neonatal mortality.

24 cations are a major driver of stillbirth and neonatal mortality.

25 .6% (95%CI 3.4-11.7; p = 0.001) reduction in neonatal mortality.

26 t-dependent glycogen synthesis and increased neonatal mortality.

27 defect worldwide and are a leading cause of neonatal mortality.

28 of PE, placenta-mediated complications, and neonatal mortality.

29 g countries to identify strategies to reduce neonatal mortality.

30 atal mortality and 1.90 (1.32-2.73) for post-neonatal mortality.

31 atal mortality and 2.50 (1.48-4.22) for post-neonatal mortality.

32 to SSRIs during pregnancy and stillbirth or neonatal mortality.

33 ciated with preterm birth, fetal injury, and neonatal mortality.

34 (SSRIs) increases the risk of stillbirth or neonatal mortality.

35 ulted in acute respiratory distress and high neonatal mortality.

36 ight, and a Poisson model for the outcome of neonatal mortality.

37 hand washing, and appropriate cord care) and neonatal mortality.

38 l ultrasound or neonatal assessment, and (3) neonatal mortality.

39 oducing mucus obstruction, inflammation, and neonatal mortality.

40 al Bangladesh, which has a moderate level of neonatal mortality.

41 nment organisation infrastructures to reduce neonatal mortality.

42 a, aimed at modifying practices and reducing neonatal mortality.

43 5B protein expression, bacterial burden, and neonatal mortality.

44 understanding of the levels of and trends in neonatal mortality.

45 health system, low health-care use, and high neonatal mortality.

46 a major cause of severe maternal illness and neonatal mortality.

47 coincident with delayed parturition and 100% neonatal mortality.

48 cies and contributes to approximately 50% of neonatal mortality.

49 ucation and infant mortality, especially for neonatal mortality.

50 t level, geographical location, and previous neonatal mortality.

51 ring coincident with prolonged gestation and neonatal mortality.

52 ic and neonatal care services did not affect neonatal mortality.

53 Facility delivery should reduce early neonatal mortality.

54 ly associated with a small decrease in early neonatal mortality.

55 s-educated women, except first-day and early neonatal mortality.

56 ress the knowledge gap on specific causes of neonatal mortality.

57 er 100 000 livebirths, and minimal change in neonatal mortality.

58 Few data exist for neonatal mortality.

59 ntly 10.7% of under-5 mortality and 15.1% of neonatal mortality.

60 d lead to a reduction of the order of 25% in neonatal mortality.

61 relative socioeconomic inequalities in early neonatal mortality (0 to 6 days) and facility delivery a

62 ity (0.45, 0.17-0.73) and a 33% reduction in neonatal mortality (0.67, 0.59-0.74).

63 0.63, 95% CI 0.32-0.94), a 23% reduction in neonatal mortality (0.77, 0.65-0.90), and a 9% non-signi

64 cline from 1990 to 2010 is 2.1% per year for neonatal mortality, 2.3% for postneonatal mortality, and

65 In the mid-2000s, neonatal mortality accounted for almost 40% of deaths of

66 Neonatal mortality accounts for 43% of global under-five

67 Neonatal mortality accounts for 43% of under-five mortal

68 Neonatal mortality accounts for a high proportion of dea

69 was associated with a relative reduction in neonatal mortality (adjusted odds ratio 0.52, 95% CI 0.3

70 es is associated with relative reductions in neonatal mortality among home births in underserved, rur

71 very kit use or clean delivery practices and neonatal mortality among home births.

72 The primary outcome was 28-day neonatal mortality among infants less than the 5th perce

73 Fresh stillbirth and neonatal mortality among low-birthweight and preterm bab

74 irths were associated with lower maternal or neonatal mortality among WHO member states.

75 population) were 1.83 (95% CI 1.34-2.50) for neonatal mortality and 1.90 (1.32-2.73) for post-neonata

76 or preterm were 6.82 (95% CI 3.56-13.07) for neonatal mortality and 2.50 (1.48-4.22) for post-neonata

77 major demographic metrics (adult mortality, neonatal mortality and birthrate) between the two period

78 were used to explore the association between neonatal mortality and clean delivery kit use or clean d

79 el by use of current levels of and trends in neonatal mortality and historic or annual rates of reduc

80 is associated with substantial reductions in neonatal mortality and low birthweight under routine mal

81 nets are associated with a decreased risk of neonatal mortality and lower birth-weight.

82 likely to result in significant decreases in neonatal mortality and might allow Malawi to meet its go

83 on-induced preterm birth is a major cause of neonatal mortality and morbidity and leads to preterm pr

84 extreme prematurity is the leading cause of neonatal mortality and morbidity due to a combination of

85 Sepsis is a major cause of neonatal mortality and morbidity worldwide.

86 Preterm birth is the major cause of neonatal mortality and morbidity, and bacterial infectio

87 Preterm birth is a major contributor to neonatal mortality and morbidity, and infection is a maj

88 Preterm birth (PTB) is a major cause of neonatal mortality and morbidity, often triggered by cho

89 the scope of midwifery; reduced maternal and neonatal mortality and morbidity, reduced stillbirth and

90 Preterm birth (PTB) is the leading cause of neonatal mortality and morbidity, with few prevention an

91 m labor (PTL), associated with high rates of neonatal mortality and morbidity.

92 eveloping world, contributing to substantial neonatal mortality and morbidity.

93 ant factor contributing to preterm birth and neonatal mortality and morbidity.

94 e is an important modifiable risk factor for neonatal mortality and morbidity.

95 weeks of gestation, is the leading cause of neonatal mortality and morbidity.

96 mic encephalopathy (HIE) is a major cause of neonatal mortality and morbidity.

97 der with an important impact on maternal and neonatal mortality and morbidity; the other type present

98 We also compared changes in neonatal mortality and newborn care practices in interve

99 cleansing with 4% chlorhexidine solution on neonatal mortality and omphalitis in rural settings of s

100 Outcomes of interest included maternal and neonatal mortality and other intermediate measures such

101 an help to substantially reduce maternal and neonatal mortality and stillbirths in LMICs.

102 we assessed was the levels of and trends in neonatal mortality and the global and regional NMRs from

103 ty, perinatal mortality, first-day and early neonatal mortality, and antepartum and intrapartum still

104 creases in institutional stillbirth rate and neonatal mortality, and decreases in quality of care.

105 ection-associated PTB, 101.10 prevented PTB, neonatal mortality, and fetal brain inflammation.

106 Preterm birth is the leading cause of neonatal mortality, and is frequently associated with in

107 nt Goal 2030 targets for maternal mortality, neonatal mortality, and mortality in children younger th

108 with HLHS born far from a CSC have increased neonatal mortality, and most of this mortality is presur

109 h interventions coverage, under-5 mortality, neonatal mortality, and prevalence of under-5 stunting.

110 predictors of effect on maternal mortality, neonatal mortality, and stillbirths.

111 Preterm birth (PTB) is the leading cause of neonatal mortality, and surviving infants are at increas

112 Universal ultrasound would also prevent 7.89 neonatal mortalities annually.

113 rica (SSA), where the levels of maternal and neonatal mortality are highest globally despite rapid in

114 tudies, particularly from settings with high neonatal mortality, are needed to determine whether targ

115 y rates were not correlated with maternal or neonatal mortality at a country level.

116 d deaths to produce estimates of under-5 and neonatal mortality at a resolution of 5 x 5 km grid cell

117 However, neonatal mortality at optimal birth weight was significa

118 00 live births) or neonatal mortality rates (neonatal mortality before age 28 days per 1000 live birt

119 Neonatal mortality before discharge from the hospital.

120 With these estimates of neonatal mortality between 1990 and 2017, we then aimed

121 wed significant reductions in stillbirth and neonatal mortality but did not report the overall effect

122 munity mobilisation interventions may reduce neonatal mortality but the contribution of referral comp

123 of pregnancy and delivery complications and neonatal mortality, but the mechanisms are unclear.

124 substantial and growing share of under-5 and neonatal mortality, but they are largely neglected in th

125 SXXI was not associated with early (<1 week) neonatal mortality, but was associated with a reduction

126 n of low-birth-weight (LBW) newborns reduces neonatal mortality by >40% due to prevention of primaril

127 sociated with a reduction in late (<28 days) neonatal mortality by 0.139 deaths per 1000 livebirths (

128 with caesarean section capabilities reduced neonatal mortality by 11.4 deaths per 1000 livebirths (s

129 mme settings in Ghana and south Asia reduced neonatal mortality by 12% (95% CI 5-18).

130 allow Malawi to meet its goal of halving its neonatal mortality by 2030.

131 s established a national goal of halving its neonatal mortality by 2030.

132 spills that occur before conception increase neonatal mortality by 38.3 deaths per 1,000 live births,

133 al to test whether early BCG-Denmark reduces neonatal mortality by 45%.

134 imed to estimate the levels of and trends in neonatal mortality by use of a statistical model that ca

135 ce and the risk ratio between SGA status and neonatal mortality, calculated using Poisson regression

136 en aimed to assess how different targets for neonatal mortality could affect the burden of neonatal m

137 an intention-to-treat analysis comparing the neonatal mortality (day 0-27) per 1,000 live births in i

138 We examine neonatal mortality (death within the first 28 days after

139 the year after pregnancy were noted for both neonatal mortality (deaths within 0 to 27 days; IRR, 2.7

140 cline occurred in the 1-59 months age group; neonatal mortality declined more slowly (from 50 to 23 d

141 tion in rural Bangladesh showed no effect on neonatal mortality, despite a similar intervention havin

142 thweight infants in the intervention groups, neonatal mortality did not decrease in this group, and i

143 care will reduce intrapartum stillbirth and neonatal mortality, especially in resource-poor settings

144 al mortality ratio, and under-5, infant, and neonatal mortality, especially in socioeconomically disa

145 Neonatal mortality fell by 51% from 16.2 deaths per 1000

146 comes were defined as spontaneous abortions, neonatal mortality, fetal deaths, admission to the neona

147 Secondary outcomes were neonatal mortality, fetal loss (abortions and stillbirth

148 We developed new estimates of child and neonatal mortality for 1998-2009 using a 2010 household

149 provided significantly greater reductions in neonatal mortality for female neonates compared with mal

150 We estimated child and neonatal mortality for the years 2000-14 using five dist

151 eonatal mortality could affect the burden of neonatal mortality from 2018 to 2030.

152 ysis, we used all publicly available data on neonatal mortality from databases compiled annually by t

153 but also renal tubular defects that lead to neonatal mortality from renal failure.

154 f neonatal deaths and increases risk of post-neonatal mortality, growth failure, and adult-onset non-

155 Reduction of neonatal mortality has been slower than that for materna

156 come countries, reductions in stillbirth and neonatal mortality have been slow.

157 natal death and absolute rate differences in neonatal mortality (i.e., the excess number of neonatal

158 can reduce intrapartum stillbirth and early neonatal mortality, if delivered in a high-quality healt

159 ost regions accelerated progress in reducing neonatal mortality in 2000-17 versus 1990-2000.

160 erogeneity in absolute levels of under-5 and neonatal mortality in 2015, as well as the annualised ra

161 and used them to project rates of child and neonatal mortality in 2035 in 74 Countdown to 2015 prior

162 d driving time) from birth center to CSC and neonatal mortality in 463 infants with HLHS.

163 ath and greater absolute rate differences in neonatal mortality in all gestational-age strata.

164 rative newborn care is effective in reducing neonatal mortality in communities with a weak health sys

165 Preterm birth, the major cause of neonatal mortality in developed countries, is associated

166 Public health strategies aimed at reducing neonatal mortality in high-income countries may need to

167 ework by applying it to the case of reducing neonatal mortality in India.

168 Neonatal mortality in infants born <10 minutes from a CS

169 INTERPRETATION: The reduction in neonatal mortality in intervention clusters occurred aga

170 Sepsis is a leading cause of neonatal mortality in low-resource settings.

171 ate the association of facility quality with neonatal mortality in Malawi.

172 Chlorhexidine umbilical cord washes reduce neonatal mortality in south Asian populations with high

173 number of outbreaks of vesicular disease and neonatal mortality in swine.

174 rt the use of chlorhexidine for reduction of neonatal mortality in this east African setting, which m

175 lly-representative empirical data related to neonatal mortality, including data from vital registrati

176 uring lockdown (p=0.0002), and institutional neonatal mortality increased from 13 per 1000 livebirths

177 Neonatal mortality increased when pregnancies continued

178 were associated with increased rates of post-neonatal mortality, infant mortality, and under-5 mortal

179 Reducing neonatal mortality is an essential part of the third Sus

180 Neonatal mortality is double the global average.

181 Maternal and neonatal mortality is high in Africa, but few large, pro

182 ity health workers in reducing perinatal and neonatal mortality is well established, evidence in supp

183 fant mortality was similar to the 2%-4% post-neonatal mortality observed in this region.

184 associated with a 16% relative reduction in neonatal mortality (odds ratio 0.84, 95% CI 0.77-0.92).

185 1 per 1000 in control areas), a reduction in neonatal mortality of 38% (risk ratio, 0.62 [95% CI, 0.4

186 l and child healthcare led to a reduction in neonatal mortality of almost the hypothesized 25% in sma

187 nificantly increased risk of pregnancy loss, neonatal mortality, or malformation.

188 effects and no benefit for gestation length, neonatal mortality, or placental inflammation.

189 RIs during pregnancy and risk of stillbirth, neonatal mortality, or postneonatal mortality.

190 The primary outcome was neonatal mortality over a 2 year follow up.

191 Average rates of infant, neonatal, and post-neonatal mortality over the study period were 55.2, 30.7

192 -level heterogeneity in under-5, infant, and neonatal mortality over time in Mozambique.

193 sociated with reduction in both maternal and neonatal mortality (p=0.026 and p=0.011, respectively).

194 suggesting that the effects of oil spills on neonatal mortality persist for several years after the o

195 ns can reduce the three most common cause of neonatal mortality--preterm, intrapartum, and infection-

196 ion of maternal educational disparities with neonatal mortality (proportion eliminated: 75%-81%) than

197 nificantly associated with decreased risk of neonatal mortality (protective efficacy [PE] 18%, 95% CI

198 -10.1; 95% CI, -16.8 to -3.4; P = .003) and neonatal mortality rate (adjusted slope coefficient, -0.

199 ssociated with a nonsignificant reduction in neonatal mortality rate (MRR, 0.70; 95% confidence inter

200 Africa by assessing the effect on all-cause neonatal mortality rate (NMR) and essential newborn-care

201 rates and maternal mortality ratio (MMR) and neonatal mortality rate (NMR) were inversely correlated.

202 rview (measured by stillbirth rate [SBR] and neonatal mortality rate [NMR]) and mean time taken to co

203 We found no significant difference in neonatal mortality rate between the chlorhexidine group

204 cluded changes in newborn-care practices and neonatal mortality rate compared with the control group.

205 The neonatal mortality rate during this period was 30 per 10

206 Neonatal mortality rate from periviability was 96.2% and

207 The neonatal mortality rate in Andhra Pradesh was 44 per 1,0

208 However, neonatal mortality rate in Whites was 0.78 per 1,000 liv

209 ity rate is 46 per 1000 live births, and the neonatal mortality rate is 33 per 1000 live births.

210 increased from $127 per life-year saved at a neonatal mortality rate of 60 deaths per 1000 livebirths

211 onal age and calculate its impact on overall neonatal mortality rate over a 12-year period (1998-2009

212 Neonatal mortality rate per 1000 live births was 11.4.

213 ive for lower-middle-income countries in all neonatal mortality rate scenarios modelled, and at least

214 The neonatal mortality rate was 11.78 (95% CI 5.92-23.46) pe

215 ong the 6,686 neonates analyzed, the overall neonatal mortality rate was 17 per 1,000 live births.

216 The neonatal mortality rate was 42 deaths per 1000 livebirth

217 Their proportion to the total neonatal mortality rate was 48.6%; out of 298 periviable

218 Neonatal mortality rate was compared with generalised es

219 Neonatal mortality rate was most strongly associated wit

220 The neonatal mortality rate was significantly lower in the i

221 The final model included log(neonatal mortality rate) (cubic spline), log(low birthwe

222 their outcomes (institutional stillbirth and neonatal mortality rate), and quality of intrapartum car

223 ital beds per 1,000 people) and performance (neonatal mortality rate).

224 unt rate, protective effectiveness, baseline neonatal mortality rate, and implementation costs.

225 (HSA) level variation in the expected early neonatal mortality rate, based on gestational age (GA) a

226 h (day 0) and within week 1 varied little by neonatal mortality rate, income, or region.

227 Heterogeneity was greater for neonatal mortality rate, with only seven of 11 provinces

228 nce with singletons was especially stark for neonatal mortality (rate ratio 5.0, 95% CI 4.5-5.6).

229 days postpartum per 100,000 live births) or neonatal mortality rates (neonatal mortality before age

230 sehold surveys, to estimate country-specific neonatal mortality rates (NMR; the probability of dying

231 Neonatal mortality rates (NMRs) in countries of low and

232 rtality in south Asian populations with high neonatal mortality rates and predominantly home-based de

233 ish the trends in U5MR from which infant and neonatal mortality rates are generally derived.

234 n Africa has the world's highest under-5 and neonatal mortality rates as well as the highest naturall

235 By producing under-5 and neonatal mortality rates at multiple levels of geospatia

236 We compared week-specific neonatal mortality rates by gestational age at delivery.

237 ffect of chlorhexidine with dry cord care on neonatal mortality rates in Zambia.

238 rd applications did not significantly reduce neonatal mortality rates in Zambia.

239 he potential cost-effectiveness for baseline neonatal mortality rates of 20-60 deaths per 1000 livebi

240 y cost effective for low-income countries at neonatal mortality rates of 30 or more deaths per 1000 l

241 The number of countries with neonatal mortality rates of fewer than 11 per 1000 liveb

242 If all high-burden countries achieved the neonatal mortality rates of their region's fastest progr

243 r sub-Saharan African populations with lower neonatal mortality rates or mostly facility-based delive

244 Maternal and neonatal mortality rates remain high in many low-income

245 , intra-, and postpartum period and computed neonatal mortality rates using the most recent Demograph

246 infants receive early BCG in areas with high neonatal mortality rates.

247 s and lower (<30 deaths per 1000 livebirths) neonatal mortality rates.

248 the population and targeting continued high neonatal mortality rates.

249 Neonatal mortality reduced from 35.0 to 30.5 deaths per

250 However, the lower pace of neonatal mortality reduction would prevent most countrie

251 ch trends and subnational variation in early neonatal mortality reflect differences in the prevalence

252 Neonatal mortality remained high despite better care pra

253 We modelled daily neonatal mortality risk and estimated the proportion of

254 Our objective was to estimate the neonatal mortality risk associated with preterm birth wh

255 The pooled neonatal mortality risk did not differ significantly; th

256 The neonatal mortality risk of babies who were both preterm

257 st risk of neonatal death, with ongoing post-neonatal mortality risk, and important risk of long-term

258 and no significant change in the associated neonatal mortality risk, resulting in a decrease in the

259 h are the most risky for human survival, yet neonatal mortality risks are generally not reported by d

260 stillbirth (RR = 6.3, 99% CI: 4.7, 7.9), and neonatal mortality (RR = 7.6, 99% CI: 5.2, 10.1).

261 ed to accelerate their progress to reach the neonatal mortality SDG target by 2030.

262 Seven studies (8.4%) were from high neonatal mortality settings.

263 bstantial progress has been made in reducing neonatal mortality since 1990, increased efforts to impr

264 Between 1990 and 2010, the U.S ranking in neonatal mortality slipped from 29(th) to 45(th) among c

265 0 live births were inversely correlated with neonatal mortality (slope coefficient, -1.4; 95% CI, -2.

266 If each country achieves the SDG neonatal mortality target of 12 deaths per 1000 livebirt

267 arget, while 17 are not on track to meet the neonatal mortality target.

268 tes and 10 minutes was associated with lower neonatal mortality than a stable Apgar score.

269 Most states had a slower decline in neonatal mortality than in mortality among children aged

270 ventions that need to be scaled up to reduce neonatal mortality, there is a lack of clarity on the in

271 ASHAs can successfully reduce neonatal mortality through participatory meetings with w

272 t of CD71(+) erythroid splenocytes on murine neonatal mortality to endotoxin challenge or polymicrobi

273 rom foetal akinesia resulting in in utero or neonatal mortality, to milder disorders that are not lif

274 p or ITNs) at preventing low birthweight and neonatal mortality under routine programme conditions in

275 e tested the association between kit use and neonatal mortality using a pooled dataset from all three

276 We assessed neonatal mortality, utilisation, travel distance, median

277 stillbirths was 0.45%, and the incidence of neonatal mortality was 0.34%.

278 The incidence of early neonatal mortality was 12.7 per 1,000 live births during

279 Neonatal mortality was 153 (4.4%) of 3506 infants (95% C

280 ensives, the APO rate was 58.0% and fetal or neonatal mortality was 22.0%.

281 the less-than-5th-percentile infants, 28-day neonatal mortality was 225 per 1000 livebirths for the i

282 Among the whole population, 28-day neonatal mortality was 27.4 per 1000 livebirths for the

283 Maternal-fetal-neonatal mortality was determined not only by acuteness

284 Neonatal mortality was not associated with SSRI first-tr

285 Finally, an increased prevalence in neonatal mortality was observed in litters from dams lac

286 Neonatal mortality was reduced in the home-care arm by 3

287 pollutant quintiles were compared; however, neonatal mortality was significantly associated with SO2

288 Independent predictors of maternal-fetal-neonatal mortality were Acute Physiology and Chronic Hea

289 The inequalities in early neonatal mortality were compared with inequalities in po

290 loped more complications; maternal and fetal-neonatal mortality were higher.

291 Community-based interventions can reduce neonatal mortality when health systems are weak.

292 illbirth, with no corresponding reduction in neonatal mortality, when term pregnancies continue to 41

293 ated with neurodegeneration and prenatal and neonatal mortality, which could be due to excess cell de

294 cal factor and climate factors for adult and neonatal mortality, while birthrate was not affected by

295 ciently powered to detect reduction in early neonatal mortality with the number of clusters provided.

296 Preterm birth remains a common cause of neonatal mortality, with a disproportionately high burde

297 Preterm birth is a leading cause of neonatal mortality, with a variety of contributing cause

298 over, Speg mutant mice exhibited significant neonatal mortality, with increased death occurring by 2

299 PLA improve key behaviours on the pathway to neonatal mortality, with the strongest evidence for home

300 ity within 28 days post-partum and all-cause neonatal mortality within 28 days post-partum among babi

301 The primary outcomes were all-cause neonatal mortality within 28 days post-partum and all-ca